6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

NCT00826267 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: lapatinib
DRUG: BIBW 2992
DRUG: trastuzumab

Sponsor

Boehringer Ingelheim